[Nivolumab (gastric adenocarcinoma, adenocarcinoma of the gastroesophageal junction or the oesophagus) - Benefit assessment according to §35a Social Code Book V]

Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004060
Original Title: Nivolumab (Adenokarzinome des Magens, des gastrooesophagealen uebergangs oder des oesophagus)
Project Status: Completed
Year Published: 2022
English language abstract: There is no English language summary available
Publication Type: Full HTA
Country: Germany
MeSH Terms
  • Adenocarcinoma
  • Nivolumab
  • Antibodies, Monoclonal, Humanized
  • Esophageal Neoplasms
  • Esophagogastric Junction
  • Antineoplastic Agents, Immunological
  • Stomach Neoplasms
  • Immune Checkpoint Inhibitors
  • Nivolumab
  • Adenocarcinoma
  • Benefit Assessment
  • NCT02872116
Organisation Name: Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address: IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email: berichte@iqwig.de
Copyright: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.